Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., GlaxoSmithKline plc, GE Healthcare, Medtronic, Quest Diagnostics, are some of the prominent players at the forefront of competition in the biomarker test market and are profiled in MRFR Analysis.
Biomarker Test Market – Overview
The biomarker test market is growing mainly due to rising prevalence of genetic disorders. According to a recent study report published by the Market Research Future, the biomarker test market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2022).
Most healthcare professionals use diagnosis tests to clarify and support their clinical decision making. Progressively over recent years, the analytic procedure has turned out to be stronger by the need to preselect patients in light of medications and licenses. This move has come to through various factors, which incorporate propelling technology (empowering professionals to measure more particular markers of adequacy), an increased comprehension of the disease procedure, and a more prominent energy about the uniqueness of an individual’s tumour at the molecular level. Biomarkers on drug labels are improving the focus on biomarker testing by the administrative sector which is highlighted by the developing number of medications with this information on their labels.
Notably, demand for biomarkers in various technologies such as next-generation sequencing (NGS) technologies, and ultra-high throughput sequencing is the primary driver for biomarker test market. The software and hardware are the technological building blocks of biomarkers tests. The changes in emerging technologies are affecting various initiatives like, the shift to companion diagnostics, NGS and many others. Evolutions of targeted therapies, more research and development programs are supporting this trend as it has enormous potential for more Biomarker Test offerings in undeveloped countries.
Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/3570
Other push factors such as, growing prevalence of genetic diseases, growing potential of biomarkers in targeted therapies, involvement of patients in personal healthcare, and rising healthcare expenditure are also fuelling the growth of the market. Among all disease categories, recent advances in cancer care have been most closely associated with genomic medicine. Understanding the genetic mutations of individual tumour’s holds the promise of giving physicians greater capacity to prescribe specific medicines to fight specific cancer types. But there are only a few cancers and cancer types that have been associated with specific genetic mutations.
Despite these drivers, lack of awareness about the possible applications of biomarkers, regulatory framework, and lack of research and indications creating difficulties in the application are expected to hinder the growth of the market. The challenges in adopting personalized medicine are boundless. The first and foremost challenge affecting the biomarker tests landscape is coordinating the timelines. Aligning the development of a drug and diagnostic design program requires a lot of careful planning.
Biomarker Test Market – Competitive Analysis
The Biomarker Test market is currently dominated by various players. Due to rising research and development expenditure various existing and new marketers are continuously coming up with advanced products to control genetic, and other complications. The global biomarker test market is currently dominated by numerous players.
Roche is one of them by holding a strong share in the market. Roche is the world’s biggest biotech organization, with genuinely differentiated solutions in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. The consolidated qualities of pharmaceuticals and diagnostics under one rooftop have made Roche the pioneer in personalized healthcare. The company offers various products in the pharmaceutical, diagnostics and research industry such as ACCU-CHEK Safe-T-Pro lancet, Accu-Chek Multiclix Finger Pricker, Accu-Chek FastClix, Accu-Chek Softclix, and others. In February, 2015, Roche acquired Signature Diagnostics AG (Signature), a privately held company based in Potsdam, Germany. In the same year, Roche got an approval from FDA for Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema.
Novartis AG is another renowned market player in biomarker test market. The product portfolio of company includes Biosimilar’s, oncology injectable, anti-invectives, targeted therapy, cell & gene therapy, and others. In March, 2016, Novartis cancer drug gets FDA’s principal ‘biosimilar’ affirmation. Federal regulators have permitted the first “biosimilar” drug to be sold in the U.S. under a program intended to branch a new market of lower-cost substitutes to some of the most expensive treatments in healthcare. This approval of biosimilars will help many patients who are in need of these treatments.
Access Complete Report @ https://www.marketresearchfuture.com/reports/biomarker-test-market-3570
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
+1 646 845 9312
Email: [email protected]
NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.